These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. PANCR, the PITX2 Adjacent Noncoding RNA, Is Expressed in Human Left Atria and Regulates PITX2c Expression. Gore-Panter SR; Hsu J; Barnard J; Moravec CS; Van Wagoner DR; Chung MK; Smith JD Circ Arrhythm Electrophysiol; 2016 Jan; 9(1):e003197. PubMed ID: 26783232 [TBL] [Abstract][Full Text] [Related]
6. DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients. Dietrich D; Hasinger O; Liebenberg V; Field JK; Kristiansen G; Soltermann A Diagn Mol Pathol; 2012 Jun; 21(2):93-104. PubMed ID: 22555092 [TBL] [Abstract][Full Text] [Related]
7. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579 [TBL] [Abstract][Full Text] [Related]
8. PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies. Uhl B; Gevensleben H; Tolkach Y; Sailer V; Majores M; Jung M; Meller S; Stein J; Ellinger J; Dietrich D; Kristiansen G J Mol Diagn; 2017 Jan; 19(1):107-114. PubMed ID: 27939865 [TBL] [Abstract][Full Text] [Related]
9. Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma. Sailer V; Gevensleben H; Dietrich J; Goltz D; Kristiansen G; Bootz F; Dietrich D PLoS One; 2017; 12(6):e0179412. PubMed ID: 28617833 [TBL] [Abstract][Full Text] [Related]
10. Prognostic role of methylated GSTP1, p16, ESR1 and PITX2 in patients with breast cancer: A systematic meta-analysis under the guideline of PRISMA. Sheng X; Guo Y; Lu Y Medicine (Baltimore); 2017 Jul; 96(28):e7476. PubMed ID: 28700487 [TBL] [Abstract][Full Text] [Related]
11. Holmes EE; Goltz D; Sailer V; Jung M; Meller S; Uhl B; Dietrich J; Röhler M; Ellinger J; Kristiansen G; Dietrich D Clin Epigenetics; 2016; 8():104. PubMed ID: 27708722 [TBL] [Abstract][Full Text] [Related]
12. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169 [TBL] [Abstract][Full Text] [Related]
13. DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients. Nimmrich I; Sieuwerts AM; Meijer-van Gelder ME; Schwope I; Bolt-de Vries J; Harbeck N; Koenig T; Hartmann O; Kluth A; Dietrich D; Magdolen V; Portengen H; Look MP; Klijn JG; Lesche R; Schmitt M; Maier S; Foekens JA; Martens JW Breast Cancer Res Treat; 2008 Oct; 111(3):429-37. PubMed ID: 17965955 [TBL] [Abstract][Full Text] [Related]
14. Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis. Vinarskaja A; Schulz WA; Ingenwerth M; Hader C; Arsov C Urol Oncol; 2013 Jul; 31(5):622-7. PubMed ID: 21803613 [TBL] [Abstract][Full Text] [Related]
15. A DNA hypermethylation profile reveals new potential biomarkers for the evaluation of prognosis in urothelial bladder cancer. López JI; Angulo JC; Martín A; Sánchez-Chapado M; González-Corpas A; Colás B; Ropero S APMIS; 2017 Sep; 125(9):787-796. PubMed ID: 28586118 [TBL] [Abstract][Full Text] [Related]
16. Prediction efficiency of PITX2 DNA methylation for prostate cancer survival. Luan ZM; Zhang H; Qu XL Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173224 [TBL] [Abstract][Full Text] [Related]
17. HOXA9 methylation and blood vessel invasion in FFPE tissues for prognostic stratification of stage I lung adenocarcinoma patients. Lissa D; Ishigame T; Noro R; Tucker MJ; Bliskovsky V; Shema S; Beck JA; Bowman ED; Harris CC; Robles AI Lung Cancer; 2018 Aug; 122():151-159. PubMed ID: 30032824 [TBL] [Abstract][Full Text] [Related]
18. Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer. Kitchen MO; Bryan RT; Haworth KE; Emes RD; Luscombe C; Gommersall L; Cheng KK; Zeegers MP; James ND; Devall AJ; Fryer AA; Farrell WE PLoS One; 2015; 10(9):e0137003. PubMed ID: 26332997 [TBL] [Abstract][Full Text] [Related]
19. Development of a diagnostic microarray assay to assess the risk of recurrence of prostate cancer based on PITX2 DNA methylation. Schatz P; Dietrich D; Koenig T; Burger M; Lukas A; Fuhrmann I; Kristiansen G; Stoehr R; Schuster M; Lesche R; Weiss G; Corman J; Hartmann A J Mol Diagn; 2010 May; 12(3):345-53. PubMed ID: 20304943 [TBL] [Abstract][Full Text] [Related]
20. Methylated promoter DNA of CDO1 gene and preoperative serum CA19-9 are prognostic biomarkers in primary extrahepatic cholangiocarcinoma. Nakamoto S; Kumamoto Y; Igarashi K; Fujiyama Y; Nishizawa N; Ei S; Tajima H; Kaizu T; Watanabe M; Yamashita K PLoS One; 2018; 13(10):e0205864. PubMed ID: 30325974 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]